| (+)-Chloroquine |
|
|
|
| (D-Pro7)-Angiotensin I/II (1-7) |
|
|
99.95% |
| (Des-Asp1,Ile8)-Angiotensin II |
|
|
98.93% |
| (Rac)-Valsartan-d9 |
|
|
|
| (Sar1)-Angiotensin II |
|
|
99.84% |
| (Sar1,Gly8)-Angiotensin II |
|
|
|
| (Sar1,Ile4,8)-Angiotensin II |
|
|
98.23% |
| 1-Methyl-2-[(4Z,7Z)-4,7-tridecadienyl]-4(1H)-quinolone |
|
|
|
| 1-Methyl-2-[(6Z,9Z)-6,9-pentadecadienyl]-4(1H)-quinolone |
|
|
|
| 15-Keto-PGA1 |
|
|
|
| 18-Hydroxy-11-deoxy corticosterone |
|
|
|
| 2-(Aminomethyl)-4-methylphenol hydrochloride |
|
|
98.0% |
| 5-O-beta-D-Glucopyranosylmyricanol |
|
|
|
| 5-Valine-angiotensin I |
|
|
|
| [Sar1, Ile8]-Angiotensin II |
|
|
|
| [Sar1, Ile8]-Angiotensin II TFA |
|
|
99.85% |
| [Sar1,Thr8]-Angiotensin II |
|
|
|
| [Tyr(P)4] Angiotensin II |
|
|
|
| [Val4] Angiotensin III |
|
|
98.51% |
| A 779 |
|
|
99.55% |
| A-779 TFA |
|
|
|
| A-81282 |
|
|
|
| A81988 |
|
|
|
| AAA |
|
|
99.52% |
| Abz-Gly-p-nitro-Phe-Pro-OH |
|
|
99.94% |
| Alamandine |
|
|
99.90% |
| Angiogenin (108-122) |
|
|
|
| Angiotensin (1-12) (human) |
|
|
|
| Angiotensin I/II (1-5) |
|
|
|
| Angiotensin I/II (1-5) TFA |
|
|
98.49% |
| Angiotensin I/II (1-6) |
|
|
|
| Angiotensin I/II (1-6) TFA |
|
|
99.06% |
| Angiotensin II (1-4), human |
|
|
|
| Angiotensin II (1-4), human TFA |
|
|
|
| Angiotensin II (3-8), human |
|
|
|
| Angiotensin II (3-8), human TFA |
|
|
99.14% |
| Angiotensin II (5-8), human |
|
|
99.74% |
| Angiotensin II antipeptide |
|
|
|
| Angiotensin II human TFA |
|
|
98.29% |
| Angiotensin II human, FAM-labeled |
|
|
99.58% |
| Angiotensin II type 1 receptor (181-187) |
|
|
|
| Angiotensin III, human, mouse |
|
|
98.26% |
| Angiotensin III, human, mouse TFA |
|
|
99.94% |
| Angiotensinogen (1-13) (human) |
|
|
|
| Antidiabetic agent 15 |
|
|
|
| Antihypertensive agent 2 |
|
|
|
| Antihypertensive agent 3 |
|
|
|
| Arg-Glu(edans)-Ile-His-Pro-Phe-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(dabcyl)-Arg |
|
|
|
| Arg-Glu(edans)-Ile-His-Pro-Phe-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(dabcyl)-Arg TFA |
|
|
98.75% |
| AT1R antagonist 1 |
|
|
|
| AT1R antagonist 2 |
|
|
|
| AT1R antagonist 3 |
|
|
|
| AT1R antagonist 4 |
|
|
|
| AT1R-agonist-1 |
|
|
|
| AT2 receptor ligand-1 |
|
|
|
| AT2R antagonist 1 |
|
|
|
| AT2R antagonist 2 |
|
|
|
| AT2R-IN-1 |
|
|
|
| AVE 0991 |
|
|
99.91% |
| AVE 0991 sodium salt |
|
|
99.47% |
| AZ11657312 |
|
|
|
| Azilsartan mepixetil |
|
|
98.08% |
| Azilsartan mepixetil potassium |
|
|
|
| Azilsartan methyl ester |
|
|
99.27% |
| Azilsartan mopivabil |
|
|
99.56% |
| BIBS 39 |
|
|
99.70% |
| Biotin-Ahx-Angiotensin II human |
|
|
99.86% |
| BMS 183920 |
|
|
|
| BMS-248360 |
|
|
|
| BPP 5a |
|
|
|
| Brain Natriuretic Peptide (1-32), rat |
|
|
|
| Brain Natriuretic Peptide (1-32), rat acetate |
|
|
98.66% |
| BRL-36378 |
|
|
|
| Buloxibutid |
|
|
98.94% |
| Buloxibutid hydrochloride |
|
|
|
| Peptide ligase |
|
|
|
| BW A256C |
|
|
|
| C-Type Natriuretic Peptide (1-53), human |
|
|
|
| C-Type Natriuretic Peptide (1-53), human TFA |
|
|
99.94% |
| Candesartan Cilexetil-d11 |
|
|
|
| Candesartan methyl ester |
|
|
98.13% |
| CGP-42112 |
|
|
99.84% |
| CGP48369 |
|
|
|
| CI-996 |
|
|
|
| CL-329167 |
|
|
|
| CNP-38 |
|
|
99.87% |
| CR 3834 |
|
|
|
| Cytosporin A |
|
|
|
| Cytosporin C |
|
|
|
| Dehydro Olmesartan |
|
|
99.43% |
| DMP 811 |
|
|
|
| DuP-532 |
|
|
98.00% |
| E4177 |
|
|
98.82% |
| Embusartan |
|
|
|
| EMD 66684 |
|
|
|
| EMD-66684 potassium salt |
|
|
|
| Enoltasosartan |
|
|
|
| Evazarsen |
|
|
|
| Evazarsen sodium |
|
|
|
| Evazarsen sodium scrambled negative control |
|
|
|
| EXP-408 |
|
|
|
| EXP-6803 |
|
|
|
| EXP-7711 |
|
|
|
| FK-739 free base |
|
|
|
| Fonsartan |
|
|
|
| Fonsartan free acid |
|
|
|
| Forasartan |
|
|
|
| GA 0113 |
|
|
|
| GA-0056 |
|
|
|
| GSK1820795A |
|
|
99.80% |
| H-Val-Pro-Pro-OH |
|
|
99.77% |
| H-Val-Pro-Pro-OH TFA |
|
|
98.0% |
| Hippuryl-Phe-Arg-OH |
|
|
|
| ICI-D 8731 |
|
|
|
| Irbesartan hydrochloride |
|
|
|
| Irbesartan-d7 hydrochloride |
|
|
|
| KR-31080 |
|
|
|
| KR31173 |
|
|
|
| KRH-594 |
|
|
|
| L 158338 |
|
|
|
| L 681176 |
|
|
|
| L-158809 |
|
|
|
| L-159282 |
|
|
|
| L-161638 |
|
|
98.03% |
| L-162313 |
|
|
98.51% |
| L-162537 |
|
|
|
| L-162782 |
|
|
|
| L-163007 |
|
|
|
| L-163017 |
|
|
|
| L-163958 |
|
|
|
| L162389 |
|
|
99.57% |
| L162441 |
|
|
|
| Locicortolone |
|
|
|
| LVV-hemorphin-7 |
|
|
|
| LY 301875 |
|
|
|
| LY285434 |
|
|
|
| LY303336 |
|
|
|
| Mepixetil |
|
|
|
| Milfasartan |
|
|
|
| Mitolactol |
|
|
|
| Mopivabil |
|
|
99.66% |
| Nitrosoglutathione |
|
|
90.0% |
| NO-Losartan A |
|
|
98.33% |
| Norleual |
|
|
|
| Norleual TFA |
|
|
99.93% |
| Novokinin |
|
|
99.38% |
| Novokinin TFA |
|
|
|
| Nva-VYIHPF |
|
|
|
| Olmesartan impurity |
|
|
|
| Olodanrigan |
|
|
98.89% |
| Olodanrigan sodium |
|
|
|
| PD 121981 |
|
|
|
| PD 123177 |
|
|
98.14% |
| PD 123319 |
|
|
|
| PD 123319 ditrifluoroacetate |
|
|
99.34% |
| Perindopril arginine |
|
|
99.32% |
| Azilsartan mepixetil-d5 |
|
|
|
| rac-Olodanrigan |
|
|
|
| Renin FRET Substrate I |
|
|
|
| Renin substrate, angiotensinogen (1-14), rat |
|
|
|
| RG 13647 |
|
|
|
| Ripisartan |
|
|
|
| Saprisartan |
|
|
|
| Saprisartan potassium |
|
|
|
| Sar-Arg-Val-Tyr-Val-His-NH2 |
|
|
96.63% |
| SC-51316 |
|
|
|
| SL910102 |
|
|
|
| Sparsentan |
|
|
99.87% |
| Sparsentan-d5 |
|
|
|
| Spinorphin TFA |
|
|
99.44% |
| TA-606 |
|
|
|
| Talfirastide acetate |
|
|
99.76% |
| TD-0212 |
|
|
|
| TD-0212 TFA |
|
|
98.44% |
| Tetrahydro Aldosterone |
|
|
99.0% |
| Tolmesoxide |
|
|
|
| Tolonidine |
|
|
99.59% |
| Tonlamarsen |
|
|
|
| TRV-120027 |
|
|
98.21% |
| TRV-120027 TFA |
|
|
99.62% |
| TRV055 |
|
|
99.47% |
| TRV055 hydrochloride |
|
|
98.88% |
| TRV056 |
|
|
98.06% |
| UR-7247 |
|
|
|
| Valsartan Ethyl Ester |
|
|
99.70% |
| Valsartan methyl ester |
|
|
99.39% |
| YM-358 hydrate potassium |
|
|
|
| YS-49 |
|
|
99.98% |
| YS-49 monohydrate |
|
|
99.71% |
| ZD 7155hydrochloride |
|
|
99.88% |
| ZD-6888 hydrochloride |
|
|
|
| Zilebesiran sodium scrambled negative control |
|
|
|
| Diminazene |
|
|
|
| Human Factor XIIa Beta |
|
|
|
| Tasosartan |
|
|
99.32% |
| Elisartan |
|
|
|
| Eprosartan |
|
|
99.87% |
| Eprosartan-d3 |
|
|
|
| Eprosartan-d6 |
|
|
|
| Irbesartan-d4 |
|
|
97.73% |
| Irbesartan-d6 |
|
|
|
| Irbesartan-13C,d4 |
|
|
|
| Irbesartan-d6-1 |
|
|
|
| Irbesartan-d7 |
|
|
|
| Irbesartan |
|
|
99.95% |
| trans-Tranilast |
|
|
99.63% |
| Candesartan-d4 |
|
|
98.17% |
| Candesartan-d5 |
|
|
95.50% |
| Candesartan Cilexetil |
|
|
99.66% |
| Candesartan |
|
|
98.10% |
| Olmesartan-d4 |
|
|
98.83% |
| Olmesartan-d6 |
|
|
99.26% |
| Olmesartan |
|
|
99.91% |
| Olmesartan medoxomil |
|
|
98.95% |
| Olmesartan medoxomil-d6 |
|
|
|
| Olmesartan medoxomil (Standard) |
|
|
99.35% |
| Olmesartan methyl ester |
|
|
95.0% |
| Pratosartan |
|
|
99.35% |
| Tranilast |
|
|
99.95% |
| Tranilast sodium |
|
|
99.48% |
| Telmisartan |
|
|
99.79% |
| Telmisartan-d3 |
|
|
99.77% |
| Telmisartan-d4 |
|
|
|
| Telmisartan-13C,d3 |
|
|
|
| Telmisartan-d7 |
|
|
|
| Losartan-d4 |
|
|
99.42% |
| Losartan-d2 |
|
|
|
| Losartan-d9 |
|
|
|
| Losartan |
|
|
99.41% |
| Losartan-d6 hydrochloride |
|
|
|
| Losartan-d3 Carboxylic Acid |
|
|
|
| Losartan-d4 (carboxylic acid) |
|
|
98.09% |
| Losartan potassium |
|
|
99.98% |
| Sacubitril/Valsartan |
|
|
99.96% |
| Saralasin TFA |
|
|
99.37% |
| Saralasin |
|
|
99.46% |
| Saralasin acetate hydrate |
|
|
|
| Pomisartan |
|
|
|
| Losartan Carboxylic Acid |
|
|
99.47% |
| Losartan carboxylic acid-d4 hydrochloride |
|
|
|
| Eprosartan mesylate |
|
|
99.95% |
| Sodium nitroprusside |
|
|
99.99% |
| Valsartan-d8 |
|
|
99.59% |
| Valsartan-d9 |
|
|
99.33% |
| Valsartan-d3 |
|
|
94.36% |
| Valsartan |
|
|
99.97% |
| Chymase |
|
|
|
| Benzyl benzoate |
|
|
99.98% |
| Talfirastide |
|
|
99.90% |
| Angiotensin II human acetate |
|
|
99.80% |
| Angiotensin II 5-valine |
|
|
99.35% |
| Angiotensin II/BSA |
|
|
|
| Angiotensin I/BSA |
|
|
|
| Angiotensin II human |
|
|
99.98% |
| (Asn1,Val5)-Angiotensin II |
|
|
|
| Diisononyl phthalate |
|
|
98.0% |
| Aclerastide |
|
|
99.62% |
| Azilsartan-d5 |
|
|
98.91% |
| Azilsartan-d4 |
|
|
|
| Azilsartan |
|
|
99.68% |
| Azilsartan (medoxomil monopotassium) |
|
|
98.00% |
| Azilsartan medoxomil |
|
|
99.07% |
| Fimasartan |
|
|
99.60% |
| Fimasartan-d6 |
|
|
|